Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -24933.33% is in line with its 5-year average of -23303.70%, near the high end of its 5-year range (-367800.00%–90950.00%).
155.90% below its 12-month average of 44601.26%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-06-30): -1747.48%.
EBITDA MARGIN
-24933.33%
EBITDA MARGIN AVG TTM
44601.26%
EBITDA MARGIN AVG 3Y
-4361.40%
EBITDA MARGIN AVG 5Y
-23303.70%
EBITDA MARGIN AVG 10Y
-3304.00%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-155.90%
CURRENT VS 3Y AVG
-471.68%
CURRENT VS 5Y AVG
-6.99%
CURRENT VS 10Y AVG
-654.64%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Benitec Biopharma Inc.
Market Cap
$304.88M
EBITDA Margin
-24933.33%
TTM Avg
44601.26%
3Y Avg
-4361.40%
5Y Avg
-23303.70%
Market Cap
$309.45M
EBITDA Margin
-101.16%
TTM Avg
-95.97%
3Y Avg
-88.25%
5Y Avg
-69.69%
Market Cap
$323.01M
EBITDA Margin
-184.07%
TTM Avg
-174.53%
3Y Avg
-153.81%
5Y Avg
-153.81%
Market Cap
$286.40M
EBITDA Margin
-1475.69%
TTM Avg
-1475.69%
3Y Avg
-2002.71%
5Y Avg
-1922.41%
Market Cap
$287.58M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$328.40M
EBITDA Margin
-285.23%
TTM Avg
-308.13%
3Y Avg
-415.00%
5Y Avg
-335.56%
Market Cap
$281.16M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
Market Cap
$274.05M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | $304.88M | -24933.33% | 44601.26% | -4361.40% | -23303.70% |
| Standard BioTools Inc. (LAB)vs › | $309.45M | -101.16% | -95.97% | -88.25% | -69.69% |
| CapsoVision, Inc. (CV)vs › | $323.01M | -184.07% | -174.53% | -153.81% | -153.81% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $290.87M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.40M | -1475.69% | -1475.69% | -2002.71% | -1922.41% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $287.58M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $328.40M | -285.23% | -308.13% | -415.00% | -335.56% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.05M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $279.74M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
Gross Margin
0.0%
EBITDA Margin
-24933.3%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -1747.48% |
| 2024-06-30 | 90950.00% |
| 2023-06-30 | -63800.00% |
| 2023-03-31 | -7866.67% |
| 2022-12-31 | -39342.86% |
| 2022-03-31 | -6970.83% |
| 2021-12-31 | -18888.00% |
| 2021-06-30 | -187650.00% |
| 2021-03-31 | -367800.00% |
| 2020-12-31 | -314400.00% |
| 2020-09-30 | -4723.64% |
| 2020-06-30 | 7002.50% |
| 2020-03-31 | -7200.01% |
| 2019-12-31 | -2675.34% |
| 2019-09-30 | -3239.43% |
| 2019-06-30 | -226.91% |
| 2019-03-31 | -302.92% |
| 2018-12-31 | 53.15% |
| 2018-09-30 | 54.60% |
| 2018-06-30 | -180.76% |
| 2018-03-31 | -2711.68% |
| 2017-12-31 | -1692.13% |
| 2017-09-30 | -3555.56% |
| 2017-06-30 | -4533.88% |
| 2017-03-31 | -1881.31% |
| 2016-12-31 | -3955.93% |
| 2016-09-30 | -5477.71% |
| 2016-06-30 | -8852.07% |
| 2016-03-31 | -7106.97% |
| 2015-12-31 | -8191.69% |
| 2015-09-30 | -5389.55% |
| 2015-06-30 | -1227.80% |
| 2015-03-31 | 14217.98% |
| 2014-12-31 | -847.42% |
| 2014-09-30 | -847.42% |
| 2014-06-30 | -307.64% |
| 2014-03-31 | -307.64% |
| 2013-12-31 | -1711.18% |
| 2013-09-30 | -1710.86% |
| 2013-06-30 | -156.61% |
| 2013-03-31 | -156.61% |
| 2012-12-31 | -341.59% |
| 2012-09-30 | -341.59% |
